
| |
|
| |
|
| |
|
REFERENCES
1.Patel S, Lyons AR, Hosking DJ. Drugs used in the treatment of metabolic bone disease: clinical pharmacology and therapeutic use. Drugs. 1993;46:594-617.
2.Albright F, Reifenstein EC. The parathyroid glands and metabolic bone disease. Baltimore: Williams & Wilkins; 1948.
3.Dempster DW, Shane E, Horbert W et al. A simple method for correlative light and scanning electron microscopy of human iliac crest bone biopsies: qualitative observations in normal and osteoporotic subjects. J Bone Miner Res. 1986; 1:15-21.
4.Wasnich RD et al. Osteoporosis: critique and practicum. Honolulu: Banyan Press; 1989:179-213.
5.Gambert SR, Schultz BM, Hamdy RC. Osteoporosis: clinical features, prevention, and treatment. Endocrinol Metab Clin North Am. 1995; 24:317-71
6.Meier D. Disorders of skeletal aging. In: Cassel CK, Reisenberg DE, Sorensen LB et al, eds. Geriatric medicine. 2nd ed. New York: Springer Verlag; 1990:164-183.
7.Birge SJ. Osteoporosis and hip fracture. Clin Geriatr Med. 1993; 9:69-86.
8.Riggs BL, Melton LJ. The prevention and treatment of osteoporosis. N Engl J Med. 1992; 327:620-7.
9.Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med. 1986; 314:1676-84.
10.Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med. 1991; 90:107-10.
11.Physician's Guide to Prevention and Treatment of Osteoporosis. NOF Guidelines.
12.Reid Ian R. Glucocorticoid osteoporosis-mechanisims and management. European Journal of Endocrinology. 1997;137:209-217.
13.American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996; 39:1791-1801
14.Bootsma GP, Dekhuijzen PNR, Festen J, Van Herwaarden CLA. Effects of inhaled corticosteroids on bone. Netherlands Journal of Medicine. 1997;50(6):254-260.
15.Gennari C, Martini G, Nuti R. Secondary Osteoporosis. Aging 1998;10(3);214-224.